KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) EBT (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of EBT data on record, last reported at $208.5 million in Q4 2025.

  • For Q4 2025, EBT rose 56.49% year-over-year to $208.5 million; the TTM value through Dec 2025 reached -$193.1 million, down 141.05%, while the annual FY2025 figure was -$627.9 million, 233.49% down from the prior year.
  • EBT reached $208.5 million in Q4 2025 per JAZZ's latest filing, up from -$735.6 million in the prior quarter.
  • Across five years, EBT topped out at $208.5 million in Q4 2025 and bottomed at -$735.6 million in Q2 2025.
  • Average EBT over 5 years is -$13.6 million, with a median of $38.1 million recorded in 2022.
  • Peak YoY movement for EBT: crashed 658.41% in 2022, then skyrocketed 771.16% in 2023.
  • A 5-year view of EBT shows it stood at -$44.8 million in 2021, then plummeted by 658.41% to -$340.0 million in 2022, then skyrocketed by 118.1% to $61.5 million in 2023, then surged by 116.52% to $133.2 million in 2024, then soared by 56.49% to $208.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were $208.5 million in Q4 2025, -$735.6 million in Q2 2025, and $133.2 million in Q4 2024.